Effects of terlipressin on the aquaretic system: Evidence of antidiuretic effects

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 5, 2008, Pages

  Krag, Aleksander ^a   Bendtsen, Flemming ^a   Pedersen, Erling Bjerregaard ^b   Holstein Rathlou, Niels Henrik ^c   Møller, Søren ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b HOLSTEBRO HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aquaporin 2; Ascites; Cirrhosis; Hepatorenal syndrome; Vasopressin

Indexed keywords

AQUAPORIN 2; CREATININE; PLACEBO; SODIUM; TERLIPRESSIN; VASOPRESSIN V2 RECEPTOR;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ANTIDIURESIS; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIURESIS; FLUID INTAKE; FREE WATER CLEARANCE; HEPATORENAL SYNDROME; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; URINARY EXCRETION; URINE OSMOLALITY; WATER LOADING;

EID: 57349101805     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90407.2008     Document Type: Article

References (25)

1. Esteva-Font C, Baccaro ME, Fernandez-Llama P, Sans L, Guevara M, Ars E, Jimenez W, Arroyo V, Ballarin JA, Gines P. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology 44: 1555-1563, 2006.
2. Fenton RA, Knepper MA. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol Rev 87: 1083-1112, 2007.
3. Forsling ML, Aziz LA, Miller M, Davies R, Donovan B. Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 85: 237-244, 1980.
4. Gadano A, Moreau R, Vachiery F, Soupison T, Yang S, Cailmail S, Sogni P, Hadengue A, Durand F, Valla D, Lebrec D. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 26: 1229-1234, 1997.
5. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14: 153-158, 2002.
6. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 203: 72-79, 1994.
7. Jalan R, Mookerjee R, Cheshire L, Williams R, Davies N. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial (Abstract). J Hepatol 46: 95, 2006.
8. Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, Bichet DG, Marumo F. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 332: 1540-1545, 1995.
9. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 46: 1863-1871, 2007.
10. Lote CJ, McVicar AJ, Thewles A. Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. J Physiol 391: 407-418, 1987.
11. Mallie JP, Bichet DG, Halperin ML. Effective water clearance and tonicity balance: the excretion of water revisited. Clin Invest Med 20: 16-24, 1997.
12. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, Soriano G, Terra C, Fabrega E, Arroyo V, Rodes J, Gines P. Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134: 1352-1359, 2008.
13. Moller S, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 25: 316-328, 1996.
14. Moller S, Norgaard A, Henriksen JH, Frandsen E, Bendtsen F. Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology 40: 811-819, 2004.
15. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 43: 385-394, 2006.
16. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205-244, 2002.
17. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 274: 32248-32257, 1999.
18. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36: 941-948, 2002.
19. Pedersen EB, Danielsen H, Spencer ES. Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension. Eur J Clin Pharmacol 26: 543-547, 1984.
20. Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol 280: F860-F867, 2001.
21. Rai T, Sekine K, Kanno K, Hata K, Miura M, Mizushima A, Marumo F, Sasaki S. Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol 8: 1357-1362, 1997.
22. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56: 1310-1318, 2007.
23. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gulberg V, Sigal S, Teuber P. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360-1368, 2008.
24. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology 105: 599-612, 2006.
25. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodes J. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33: 43-48, 2000.